Intercytex Share Discussion Threads

[tonyknaggs] 18/3/2011 18:18

I have emailed Steve Holgate - let's see

just a reminder of where we are...who owns this private enterprise??

November 2010

INTERCYTEX REFORMS AS U.S. DEPARTMENT OF DEFENSE FUNDS VAVELTA® SCAR THERAPY TRIALS FOR INJURED SOLDIERS

Manchester, UK, 11 November 2010.....Intercytex, the regenerative medicine company, announces that it has reformed as a private enterprise and that its lead product, the cell therapy (VAVELTA®) will be evaluated by the US military to help treat injured soldiers.

Battlefield mortality has decreased from 30% in World War II to less than 10% in present day conflicts, partly as a result of better medical care. Sadly, this increased survival has been associated with a rise in the number of patients with chronic disabilities including burn and trauma scars. Burns account for approximately 10% of all combat casualties* and Improvised Explosive Devices (IEDs), which are an increasingly common feature of today's conflicts, are associated with extensive traumatic skin loss. As a result, burn and trauma scar contractures (where skin around the wound contracts, thickens and becomes inelastic) are a significant and growing problem for injured war heroes.

'I am really delighted to announce the relaunch of Intercytex on Armistice Day since our lead product, VAVELTA®has the potential to make a real difference to the lives of injured troops' commented Dr Kemp, Intercytex' new Chief Executive Officer. VAVELTA® has already been used in a small number of patients suffering from scar contractures and the outcome of these treatments has led to this Phase II trial in military personnel with burn scars. The work is funded by a significant agreement from the US Department of Defence and the clinical trial is scheduled to begin at Pittsburgh University Hospital, US, in 2011 in partnership with the McGowan Institute for Regenerative Medicine.

In addition to the US trial, a grant from the UK Technology Strategy Board has been awarded to Intercytex in collaboration with Lt COL Steve Jeffery, a consultant plastic surgeon, to develop a clinical trial application to examine VAVELTA® in scar patients in the UK. The intention is to begin this trial at Queen Elizabeth Hospital, Birmingham, UK, later in 2011.

As well as developing treatments for burn and trauma scars, Intercytex is also planning to evaluate VAVELTA® in patients with a rare genetic skin disorder called Dystrophic Epidermolysis Bullosa (DEB). In DEB the skin and internal body linings blister at the slightest impact, causing painful open wounds. This devastating and often fatal disease affects approximately 1,000 patients in the UK alone. The clinical trial is expected to start in London at the end of the year and is funded jointly by The Technology Strategy Board and the patient charity DebRA.

VAVELTA® is designated as one of the first Advanced Therapy Medicinal Products (ATMP) by the European Medical Agency and has already been used in compassionate use programmes and via hospital exemption schemes in over 100 patients in a variety of indications.

[hyper al] 18/3/2011 17:14

I have not been informed of anything by the company, including this.



How can they sell my shares without informing me?

[oralmex] 18/3/2011 13:32

but it's a compulsory event not one i can vote on

[oralmex] 18/3/2011 13:31

just received this in my nominee account:

Regenerative Medicine Assets Limited (RMA) has now completed the sale of all its assets as detailed in its announcement dated 7th December 2009.

Following the realisation of its assets, RMA has been left with insufficient cash to settle all outstanding creditors, however in order to achieve a solvent Liquidation of the Company, certain creditors have agreed to reduce their claims.

The Board of Directors consider that it is now appropriate to seek shareholder approval to place the Company into MVL.

The MVL is subject to shareholder approval at a General Meeting of the Company to be held on 30th March 2011. Following such approval, it is anticipated that David Merrygold and Stephen Holgate of PFK (UK) LLP will be appointed as Joint Liquidators to the Company.

Please note that the admission of the RMA shares to trading on the Alternative Investment Market was cancelled on 8th January 2010.

The Board have announced that while they do not anticipate any distribution will be made to RMA shareholders as a result of the MVL, it will allow the Company to be liquidated in an orderly process and allow shareholders to recognise their losses.

We will update you in due course upon receipt of any further information from the Company or its Liquidators.

[ph1ts] 18/3/2011 12:27

oralmex - My understanding is that the new company is the one they are liquidating, not the new Intercytex.

[oralmex] 18/3/2011 12:02

some may remember that on the programme working lunch on bbc2, the company told Justin Urquhart Smith that we were shareholders of the new company so this is something that should perhaps be pursued but maybe you need a share certificate? or is that irrelevant and you can pursue it with your nominee account holdings? any thoughts?

[the_doctor] 18/3/2011 06:26

tonyknaggs

I once went to the trouble of posting about new owners involved in the new company. Nobody bothered to call them up

ICX went bust
Some of the management will naturally have been kept on
That doesnt mean they didnt accept the best price at the time?

Call Max Hermann at SLN

[hyper al] 18/3/2011 00:43

How can any of this be allowed?

How can the company continue operating after dumping all it's share holders and after supposedly selling almost all the company assets for the benefit of shareholders but without compensation to the shareholders?



I've had enough of this behaviour.

[whibbled] 17/3/2011 23:39

REGENERATIVE MEDICINE ASSETS ORDINARY GENERAL MEETING

DATE: 30/03/2011 TIME:: unknown PLACE: unknown


Surely this must be in contravention of the Companies Acts ?

As it appears that no further information will be received from Herr Kemp or Intercytex Ltd., may I suggest that all interested parties register complaints with the proposed Joint Liquidators at PKF(UK).

The following links give direct access to contact forms for the guys involved, via the PKF website.............


Steve Holgate (note correct spelling!)




David Merrygold

[whibbled] 17/3/2011 22:08

Just to cheer all of us up...........

Intercytex starts Phase II Clinical Trial
Wednesday, March 16 2011
Intercytex Ltd is very pleased to be able to make the following press release following the Company's relaunch in November



KING'S COLLEGE LONDON, INTERCYTEX AND DEBRA BEGIN PHASE II TRIAL WITH ICX-RHY IN PATIENTS WITH SEVERE GENETIC SKIN DISORDER, RDEB AT GUY'S HOSPITAL, LONDON

London, Manchester and Crowthorne, UK, 15 March 2011..... King's College London; the regenerative medicine company Intercytex; and the patient charity DEBRA, announce the start of a Phase II trial with the Intercytex therapy ICX-RHY to treat skin erosions in patients suffering from the severe genetic skin disorderRecessive Dystrophic Epidermolysis Bullosa (RDEB). In such patients the skin blisters at the slightest knock or rub, causing painful, open wounds which result in scarring and fusion of fingers.

The placebo controlled trial will involve 20 RDEB patients. It will be led by Professor John McGrath, Professor of Molecular Dermatology at King's College London and Honorary Consultant Dermatologist at Guy's and St Thomas' NHS Foundation Trust, London, who will administer a single series of ICX-RHYinjections or placebo around the margins of several selected skin erosions. The injections will take place at the Clinical Research Facilities at Guy's Hospital. Patients will then be assessed initially over a three month period to measure end points including time to wound closure, wound recurrence and erosion pain. The trial, which is scheduled for completion early in the autumn,is funded jointly by Intercytex, The Technology Strategy Board and DEBRA.

Professor McGrath has already used ICX-RHY successfully to treat 14 EB patients on a compassionate use basis. Commenting on the start of the trial, Prof McGrath said 'Finding out whether a new treatment can help people with EB heal their wounds faster makes this an important clinical trial. We plan to test cells called "fibroblasts" to see if injection into the skin affects wound healing. The trial represents a significant step forward in taking research from the laboratory to the clinic.'

Melissa Smith was born with RDEB and has lived with the condition for over 24 years. Melissa took part in preliminary studies with the therapy and is now preparing to participate in the Phase ll trial. Commenting on her involvement, Melissa said 'I am firmly committed to helping with these trials. When you have EB you live in constant pain. There is, of course, additional pain from the trial treatment but its short term and the therapy could offer such hope long term for me and others who live with EB.'

Ben Merrett, CEO of DEBRA, added: 'Some forms of EB, like RDEB, can be very debilitating and there is a high unmet medical need for an effective treatment. Judging by the initial patient reaction to ICX-RHY,this could be an exciting step forward in treating the disease and make a significant, long-term difference to people who lead very difficult lives.'

'I am delighted that ICX-RHY has shown such early promise in a small number of RDEB patients' commented Dr Kemp, Intercytex's Chief Executive Officer. 'ICX-RHY is designated an Orphan Product in the EU and this trial marks a very significant step towards obtaining Regulatory Approval for the treatment. In the meantime we are actively looking at ways we can make this material available to other patients who are not able to be part of this trial. In addition to EB patients, ICX-RHY has also shown to have the potential to help heal burn and trauma scars and we are also trialling it in these indications.'

One in 227 people have a defective gene that causes EB and the disease affects around 1 in 17,000 live births. It is estimated that there are half a million sufferers world wide and 5,000 people with EB in the UK. RDEB is one of the more severe, debilitating forms of the disease, with a prevalence of around 2 in 100,000.

ICX-RHYis a suspension of human dermal fibroblasts (HDFs, which are naturally derived skin cells) in cell storage medium, for injection into the skin. The newly introduced HDFs are thought to repair the extracellular matrixto improve skin structure and function.

ICX-RHYis designated as one of the first Advanced Therapy Medicinal Products (ATMP) by the European Medical Agency and has already been used in clinical trials and compassionate use programmes in over 100 patients in a variety of indications.

[gsytrader] 16/3/2011 09:18

Nor do I post very often Tony, but I certainly echo all your comments.

I lost in exess of 65,000 on this debacle, of course in the full knowlwedsge as with all penny stocks that it could bite my a....

Still the prospects were good and I guess we all got sucked in with the Pfizer talk, but what happened afterwards and the way these "directors' opearted would suggest that serious questiones need to be levelled at the AIM market and its obvious lack of regulation.

I have accepted my loss and am moving on with life, but I will never ever invest in another AIM share again as its not worth the angst.

As for the_doctor let's just say he's what I call a p....

Guess what my vote will be!

[ph1ts] 16/3/2011 07:48

Well said Tony!

[2trikky] 16/3/2011 07:20

He writes that carp 'cos he works for them, (allegedly).

[the_doctor] 15/3/2011 21:00

any of you bothered to speak to the company out of interest?

still not clear to me why some criticise the company - ICX went bust because the Phase III trial failed. That wasnt their fault

[hyper al] 15/3/2011 20:38

Because all of these are in my SIPP nominee account, I was not even informed!

Will chase my SIPP provider and vote 'NO'

[vivgav] 15/3/2011 19:44

I agree Max.

[liam74] 18/1/2011 22:57

Been reading the posts, how come they can start back up and use the same name?

[the_doctor] 04/12/2010 15:32

'ICX decided for it's own (directors) reasons not to continue'

and the fact they didnt have enough money to do anything further


'Rubbish, I was in ICX for it's AMD research and the London Project'

you invest in a company. if that company's future rests heavily on a product, then so does your investment


'When a mineral exploration company fails to get a JORC resource, it still has a business'

some might do. Others not
Reality is I'm afraid that after the failure, ICX no longer had a viable business in the shape/form it was in

'Why do the markets bother funding anything?'

because they hope for a return. I dont think there was enough left in ICX to attract investors.
It's possible that they covered up the value to take it for themselves, but I dont think that's clear.


I posted on here various details about who was investing in the assets via a new business, but few seemed interested.
Did you ever call them up to discuss etc?

[hyper al] 04/12/2010 15:23

'the market still sees no value in stem cells'
should it??

Well why should the market see any value in any untested drug or medical solution?
Why do the markets bother funding anything?

"but it was. and any investor could see that"

Rubbish, I was in ICX for it's AMD research and the London Project. I think they could have got funding for that line of research, but decided they could not be bothered and went for the easy option.

For mineral resources you have the JORC code, for drugs you have Phase I, II and III. If an explorer can't get a JORC resource it gives up and moves on to another project. ICX failed and should have moved on to it's AMD stem cell line, but instead it dumped everything. When a mineral exploration company fails to get a JORC resource, it still has a business, it finds the money via a placing and continues, OK share price takes a hammering, but it continues! Many AIM Pharmas still keep going after a Phase I, II or III failure; ICX decided for it's own (directors) reasons not to continue. ICX lab was almost unique in the UK and had lots of money spent on it!

It even appears that ABH may have taken over their old labs, although I don't have any direct evidence of that yet.

[the_doctor] 04/12/2010 14:39

safer - possibly
but less crooked??

There are more horror stories in resources

'If a metals explorer does not locate an economic resource they don't suspend the share and go into receivership, they get more funds and move onto the next exploration target.'

depends if the resource was their only asset and ended up without value
Do you really think ICX could have got funds?? It no longer had a business


'ICX should not have got into the position where it was hugely reliant upon the success of a single trial'

but it was. and any investor could see that


'You don't see a 10 million oz gold field getting sold for £750k'

you do if the gold field was found out to contain only gravel


'the market still sees no value in stem cells'
should it??


'If RENE's current trial fails, will that be the end of RENE'

maybe. I tend to think it will fail in Phase II
Whether RENE depends on what other assets it has. What prospects other products have. Whether the market wants to risk more money on it

[hyper al] 04/12/2010 14:26

the_doctor

Sorry my experience suggests that AIM resource stocks are far safer than AIM biotech/pharma

If a metals explorer does not locate an economic resource they don't suspend the share and go into receivership, they get more funds and move onto the next exploration target. They tend to have 3 or more exploration targets so they always have something to fall back on.

ICX had a few projects, but the markets don't treat biotech/pharma listed companies the same as mineral explorers and it appears ICX could not find the funds or did not try. ICX should not have got into the position where it was hugely reliant upon the success of a single trial. ICX's research and patent on the AMD cell line handed over to Pfizer or just £750k sums this sector up as an investment. You don't see a 10 million oz gold field getting sold for £750k and that is about it, the market still sees no value in stem cells!

I wish the markets did treat these companies the same as mineral explorers, it would at least give them a chance. If RENE's current trial fails, will that be the end of RENE, the way the markets treat these companies, I think it will, but it would be a total disgrace!